Participated · Series D · Aug 2025

SetPoint Medical is a commercial-stage medical technology company headquartered in Valencia, Calif., focused on therapies for chronic autoimmune diseases. Its FDA‑approved SetPoint System is the first neuroimmune modulation therapy for adults with moderate-to-severe rheumatoid arthritis, providing a device-based alternative for patients who do not respond to or cannot tolerate biologic or targeted drug therapies. The company’s proprietary integrated neurostimulation platform is designed to activate innate anti-inflammatory pathways in the vagus nerve to reduce inflammation and restore immunologic setpoint. Proceeds from the recent financing will support commercialization of the SetPoint System in select U.S. markets this year and broader national expansion in 2026, and will also fund advancement of the company’s pipeline in other autoimmune conditions. SetPoint plans to evaluate its platform for additional indications including multiple sclerosis and Crohn’s disease. In conjunction with the fundraise the company expanded its leadership team and board to support commercialization and market access efforts. SetPoint Medical is a privately held clinical-stage healthcare company focused on treating chronic autoimmune diseases. The company is developing a novel platform that stimulates the vagus nerve to activate the inflammatory reflex and produce a systemic immune-restorative effect. The SetPoint system is a miniaturized stimulation device placed on the vagus nerve through a small incision on the left side of the neck in an outpatient procedure and delivers stimulation on a preset schedule. The platform is being developed as an alternative for patients with rheumatoid arthritis who have an incomplete response to or are intolerant of biologic drugs, and is also intended for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint is advancing the RESET-RA study and preparing U.S. FDA regulatory submissions and early commercialization for the RA indication. Financially, the company recently announced an $80 million equity financing and expanded a senior secured term loan facility of up to $65 million with Runway Growth Capital to support development and early commercial activities. SetPoint Medical develops a bioelectronic medicine platform designed to stimulate the vagus nerve and activate the body’s inflammatory reflex to produce a systemic immune‑restorative effect for chronic autoimmune diseases. The company is pursuing electrical‑pulse therapies as a potentially safer, lower‑cost alternative to drugs and biologics for conditions including rheumatoid arthritis and inflammatory bowel disease. SetPoint is clinical‑stage and is advancing its technology through the RESET‑RA study, which will evaluate safety and efficacy in patients with moderate‑to‑severe RA. The $35 million financing announced will support the ongoing RESET‑RA trial and other development activities. SetPoint is privately held, was founded in 2007, and is based in Valencia, California. The articles do not disclose revenue or user metrics. SetPoint Medical is a privately held, clinical‑stage bioelectronic medicine company developing a platform that stimulates the vagus nerve to activate the inflammatory reflex and reduce systemic inflammation. The company is initially focused on a less immunosuppressive therapeutic option for patients with rheumatoid arthritis (RA) and is also developing applications for inflammatory bowel disease and other chronic autoimmune conditions. SetPoint’s investigational device is intended to offer an alternative to biologic and targeted drug therapies with potentially lower risk and cost. The company has received Breakthrough Device designation from the U.S. FDA for use in RA patients who are incomplete responders to, or intolerant of, multiple biologic drugs. Proceeds from the financing will support the RESET‑RA multicenter, double‑blind, randomized, sham‑controlled pivotal trial that will enroll up to 250 patients at 40 U.S. sites to evaluate safety and effectiveness. SetPoint converts neurostimulation of the vagus nerve into a systemic immune‑restorative effect and is positioning its platform toward regulatory‑pathway clinical validation. SetPoint Medical is developing a proprietary bioelectronic medicine platform that uses a small implanted device to activate the body’s Inflammatory Reflex and produce a systemic anti-inflammatory effect. The company’s core product is an implanted stimulator that targets the vagus nerve as an alternative to drug therapies for chronic inflammatory diseases. SetPoint has published positive results from a first‑in‑human proof‑of‑concept trial in rheumatoid arthritis in PNAS and presented positive data at the American College of Rheumatology meeting. The company positions its approach as potentially lower risk and lower cost compared with current biologic treatments. SetPoint plans to use the new financing to advance clinical development and enable its next clinical trial in rheumatoid arthritis. It is a privately held company focused on commercializing bioelectronic medicines for debilitating inflammatory diseases.

Participated · Series D · Aug 2024

Moximed's core product is the MISHA Knee System, the first implantable shock absorber designed to reduce about 30% of peak force on the knee with each walking step to relieve pain and preserve function in patients with medial knee osteoarthritis. The implant is placed during an outpatient procedure and has been shown to alleviate pain, improve function, and in some patients delay the need for total knee replacement. The company emphasizes a decade-plus of clinical research and development behind the technology and positions MISHA for patients with mild-to-moderate OA who seek joint-preserving options. Moximed intends to use recent financing proceeds to accelerate U.S. commercialization, expand commercial infrastructure, and broaden patient and surgeon access. The company highlights growing market opportunity given osteoarthritis prevalence in the U.S. and the product's clinical value proposition. Moximed is based in Fremont, California. Moximed, based in Fremont, California, commercializes the Misha knee system — described as the world’s first implantable shock absorber for the knee. The Misha device is designed for implantation during an outpatient procedure to alleviate pain, improve function, enable early weight bearing, and potentially delay total knee replacement for patients with mild-to-moderate osteoarthritis. The company says the system can preserve the native knee and address a treatment gap between conservative care and joint replacement. Moximed will use proceeds from the financing to pursue regulatory approvals and to establish commercial infrastructure for Misha. Results from the company’s pivotal study are slated for presentation on Sept. 22, 2020 at the Orthopedic Summit (OSET) in Boston. The article reports a $40M financing and additional debt financing support from Runway Growth Capital. Moximed develops unicompartmental shock-absorbing implants (KineSpring and Atlas systems) that absorb excess joint load without bone cutting or bone removal. The company reports treatment durability established to nearly nine years on initial patients, and the Atlas System is CE-marked in Europe. Moximed has fully enrolled its FDA pivotal clinical study of the KineSpring System and is currently enrolling a US IDE study of the Atlas System. The Atlas System is designed to provide approximately 30 lbs of unloading, is placed subcutaneously, and aims to preserve future treatment options. Moximed intends to use recent financing to complete FDA approval and support early US commercialization amid strong patient and surgeon interest. The company is backed by venture investors including NEA, Morgenthaler Ventures, Gilde Healthcare, GBS Venture Partners, Vertex Healthcare, Advent Life Sciences, and Future Fund. Moximed focuses on minimally invasive, joint‑preserving solutions for patients with knee osteoarthritis. Its core product is the KineSpring System, a subcutaneous joint‑unloading implant intended for pre‑arthroplasty patients who want to remain active. The KineSpring System is CE marked, available in major European markets, investigational in the U.S., and has been implanted in over 1,000 cases worldwide. The company announced a financing to support efforts to obtain FDA approval for KineSpring and to grow commercial sales in Europe. Moximed is backed by venture investors including Vertex Venture Holdings, New Enterprise Associates, Gilde Healthcare Partners, Morgenthaler Ventures, and GBS Venture Partners. Management cites clinical evidence from its GOAL Study and strong patient interest in joint‑preserving treatments.

Participated · Series G · Apr 2023

Relievant Medsystems is a Minneapolis, MN-based commercial-stage medical device company focused on the diagnosis and treatment of vertebrogenic pain. Its core product is the Intracept Procedure, an FDA-cleared, commercially available treatment that uses targeted radiofrequency energy to stop the basivertebral nerve (BVN) from transmitting pain signals. The Intracept Procedure is typically performed in an outpatient surgery center, takes approximately one hour, and is intended to improve quality of life for indicated patients. Led by President and CEO Tyler Binney, the company commercializes and performs the Intracept Procedure. The company raised $50M in Series G funding. It plans to use the proceeds to expand operations and R&D efforts. Relievant Medsystems commercializes the Intracept Procedure, a minimally invasive treatment for vertebrogenic chronic low back pain supported by two Level I randomized controlled trials and long-term data beyond five years. The company completed a $70 million financing to accelerate U.S. commercialization and drive rapid commercial growth. Management said 2020 would be a record year for Relievant and expects greater adoption in 2021 following publication of five-year data showing sustained improvements in pain and function. Relievant estimates over five million U.S. CLBP patients are candidates for the Intracept Procedure and highlights the procedure’s potential to change the CLBP treatment paradigm. The company is privately held and is advancing physician adoption to make the treatment available to more patients and clinicians. Relievant Medsystems develops the Intracept Procedure, a transpedicular, minimally-invasive radiofrequency ablation targeting the basivertebral nerve to relieve chronic low back pain. The Intracept System is FDA-cleared for ablation of basivertebral nerves from L3 through S1 for patients with at least six months of pain and corresponding Modic changes. Treated patients report nearly immediate relief, and the outpatient procedure typically takes 60–90 minutes. The company plans to use new capital to commercialize the Intracept Procedure in the U.S. and to continue enrollment in its INTRACEPT Level I prospective randomized controlled trial at 20 U.S. sites. Relievant said the therapy targets more than five million indicated U.S. patients who have not responded to conservative care. The company was founded in 2006 and operates R&D and operations in Sunnyvale, CA while opening its corporate headquarters in Minneapolis, MN. Relievant Medsystems develops the INTRACEPT Intraosseous Nerve Ablation System to ablate basivertebral nerves within vertebral bodies for chronic low back pain (CLBP). The company received 510(k) clearance from the FDA for INTRACEPT in July 2016. Led by CEO Alex DiNello, Relievant is focused on commercializing INTRACEPT worldwide. The company plans to use recent financing to accelerate product, clinical and market development activities. The fundraising supports advancement of intraosseous basivertebral nerve ablation as a therapeutic option for CLBP. Relievant is positioned to move from regulatory clearance toward broader commercialization. Relievant Medsystems is a Redwood City, Calif.-based medical device company focused on basivertebral nerve ablation to treat chronic axial low back pain. It is developing the Intracept System, a minimally invasive procedure that uses radiofrequency energy delivered via percutaneous access into the vertebral body to ablate the basivertebral nerve. The company is led by CEO and President Alex DiNello. In March 2012 Relievant raised $30M in a Series D financing led by New Enterprise Associates with participation from Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures and ONSET Ventures. NEA partner Justin Klein, M.D., joined the company’s board as part of the financing. Relievant intends to use the funds to advance and expand its worldwide clinical development programs.

Participated · Equity · Feb 2019

Nuvaira develops a lung denervation system to treat obstructive lung diseases using a procedure called Targeted Lung Denervation (TLD). Its proprietary technology targets airway hyper-responsiveness, a pathophysiologic underpinning of COPD and asthma, and has demonstrated safety and feasibility in IPS-I/II, AIRFLOW-1, and the AIRFLOW-2 sham-controlled randomized trial. The Nuvaira Lung Denervation System is CE Mark approved and is under clinical investigation in the U.S.; it is not commercially available in the USA. The company will use the financing to support the pivotal AIRFLOW-3 clinical trial for FDA approval and to implement a targeted clinical development strategy in key European markets. Nuvaira closed a $79M equity financing to fund these efforts. The company is led by CEO Dennis Wahr, M.D., and recently added Lisa Rogan as senior vice president of market development. Holaira is a lung denervation company developing minimally invasive products to make breathing easier for patients suffering from obstructive lung diseases. The company is working on a novel catheter‑based system that has the potential to improve lung function, exercise capacity and quality of life for patients with chronic obstructive pulmonary disease. Founded in 2008 and led by president and chief executive officer Dennis Wahr, Holaira is based in Plymouth, MN. It recently raised $42M in Series D funding to advance its clinical program. The company intends to use the funds to support the first randomized lung denervation clinical trial with a sham control. In conjunction with the funding, Dr. Lincoln Chee of Vertex Venture Holdings joined Holaira’s board of directors. Holaira (fka Innovative Pulmonary Solutions) develops minimally invasive medical devices to treat obstructive lung diseases, including a novel catheter-based system for Targeted Lung Denervation aimed at easing breathing for COPD patients. The company is working to advance its minimally invasive product portfolio and intends to use the new capital to continue development. Holaira is led by president and CEO Dennis Wahr, M.D. and was founded in 2008. The company is based in Minneapolis, MN. Financially, Holaira completed a $10M Series C financing to support its product development efforts. Identified backers include Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners and Versant Ventures.

Participated · Equity · Dec 2018

NuoDB is a NewSQL database that looks and behaves like a traditional SQL database from the outside but is revolutionary under the covers. The company positions itself as a new class of database for a new class of datacenter. It was created by an experienced team of software experts and is described as having the support of a visionary investment team. NuoDB is based in Cambridge, MA. According to an SEC filing reported by BostInno, the company has raised a $30 million equity round. Investors named in the filing include Temenos, Hummer Winblad Venture Partners, Longworth Venture Partners, Dassault Systems, and Morgenthaler Ventures. NuoDB provides an SQL database designed for cloud-enabled and modern datacenter applications. Its ACID-compliant database distributes tasks among multiple processors and uses peer-to-peer messaging to route tasks to nodes, aiming to avoid bottlenecks and maintain application performance. The product targets geo-distributed data management and business continuity for frequent application deployments. Led by President and CEO Bob Walmsley, the company operates from Cambridge, MA and also has offices in Dublin and Belfast. NuoDB completed a $17m funding round and plans to use the proceeds to further refine its database offering and expand sales and marketing efforts. NuoDB, Inc. is a Cambridge, MA–based provider of a webscale distributed database management system designed for the cloud and the modern datacenter. Led by CEO and co‑founder Barry Morris, the company delivers a DBMS specifically built for cloud deployments and modern datacenter environments. Customers mentioned in the article include AutoZone and Zombie Studios, among others. The company received an investment from Roger Sippl; the amount of the investment is undisclosed. Roger Sippl, who co‑founded Informix and other software companies, will help NuoDB improve the product. The article does not disclose revenue, user metrics, or further financial details. NuoDB develops a distributed database management system that uses a "durable distributed cache" to scale out and avoid a single point of failure. The product runs on commodity hardware and virtual machines and became generally available in January 2013. Founded in 2010 by database architect Jim Starkey and CEO Barry Morris, the company spent 2013 getting to GA and acquiring initial customers. Since GA it has grown to about 25 commercial customers, including AutoZone, DropShip Commerce and Zombie Studios, and its free Developer Edition is used by roughly 11,000 developers. NuoDB expects its revenue to grow at least 300 percent in 2014. The company plans to use the new funding to build out its sales and marketing teams. NuoDB develops an elastically scalable database architected for the cloud using a shared‑nothing, asynchronous, peer‑to‑peer design. The product is SQL‑compliant, guarantees ACID transactions, is highly resilient, and requires minimal administration. Its architecture is intended to deliver high performance at web scale without sacrificing traditional relational features. The database is currently in beta and is slated to become generally available in Q3 2012. NuoDB plans to use new funding to advance product development as well as sales and marketing. The company was founded in 2010 and is based in Cambridge, Massachusetts.